Istradefylline

Nourianz (istradefylline) is a small molecule pharmaceutical. Istradefylline was first approved as Nourianz on 2019-08-27. It is used to treat parkinson disease in the USA. It is known to target adenosine receptor A2b, adenosine receptor A3, adenosine receptor A2a, and adenosine receptor A1. Nourianz's patents are valid until 2027-09-05 (FDA).